The Scottish Medicines Consortium (SMC) has approved Lytenava (bevacizumab gamma) for the treatment of wet age-related macular degeneration (wet AMD). It is the first licensed ophthalmic formulation of bevacizumab for use in treating wet AMD in adults in the EU and the UK and has an initial 10 years of market exclusivity. “Receiving the SMC […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!